Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 16 04:00PM ET
0.5190
Dollar change
+0.0190
Percentage change
3.80
%
Index- P/E0.30 EPS (ttm)1.71 Insider Own12.91% Shs Outstand8.65M Perf Week11.94%
Market Cap4.49M Forward P/E- EPS next Y- Insider Trans-75.28% Shs Float7.53M Perf Month-13.14%
Income2.97M PEG- EPS next Q- Inst Own3.94% Short Float1.75% Perf Quarter-14.92%
Sales21.77M P/S0.21 EPS this Y- Inst Trans-0.96% Short Ratio3.86 Perf Half Y-8.95%
Book/sh0.52 P/B1.00 EPS next Y- ROA14.17% Short Interest0.13M Perf Year-51.62%
Cash/sh0.11 P/C4.88 EPS next 5Y- ROE746.92% 52W Range0.36 - 1.50 Perf YTD-10.56%
Dividend Est.- P/FCF- EPS past 5Y55.67% ROI27.67% 52W High-65.40% Beta1.30
Dividend TTM- Quick Ratio2.56 Sales past 5Y- Gross Margin100.00% 52W Low42.31% ATR (14)0.03
Dividend Ex-Date- Current Ratio1.39 EPS Y/Y TTM107.80% Oper. Margin13.48% RSI (14)48.70 Volatility6.21% 5.59%
Employees- Debt/Eq1.38 Sales Y/Y TTM137.45% Profit Margin13.64% Recom3.00 Target Price2.00
Option/ShortNo / Yes LT Debt/Eq1.38 EPS Q/Q41.55% Payout- Rel Volume0.29 Prev Close0.50
Sales Surprise- EPS Surprise- Sales Q/Q-100.00% EarningsMay 16 AMC Avg Volume34.10K Price0.52
SMA202.20% SMA50-9.63% SMA200-19.96% Trades Volume10,016 Change3.80%
Date Action Analyst Rating Change Price Target Change
Dec-13-21Downgrade Chardan Capital Markets Buy → Neutral $2.25 → $0.40
Dec-18-20Initiated BMO Capital Markets Outperform $6
Nov-20-19Initiated Guggenheim Buy $9
May-16-24 09:52PM
04:08PM
Apr-22-24 04:01PM
Feb-06-24 07:05AM
Feb-05-24 04:01PM
08:40AM Loading…
Dec-08-23 08:40AM
Nov-28-23 04:01PM
Aug-23-23 09:48AM
Aug-11-23 04:01PM
Jul-14-23 04:01PM
May-26-23 04:01PM
May-19-23 04:01PM
May-04-23 04:01PM
Apr-27-23 07:00AM
Mar-27-23 04:01PM
05:10PM Loading…
Feb-24-23 05:10PM
Dec-14-22 05:00AM
Nov-14-22 04:01PM
Sep-26-22 04:01PM
Sep-01-22 07:00AM
Aug-15-22 04:01PM
Jul-20-22 04:01PM
Jun-29-22 12:00PM
May-27-22 04:01PM
May-17-22 07:00AM
May-16-22 04:01PM
May-10-22 07:21PM
May-09-22 07:00AM
Mar-25-22 04:15PM
Feb-04-22 11:25AM
07:00AM Loading…
07:00AM
Jan-05-22 01:38PM
Dec-31-21 07:07PM
06:02PM
02:53PM
01:15PM
Dec-30-21 05:57PM
03:31PM
10:00AM
Dec-29-21 11:46PM
05:57PM
04:30PM
10:45AM
Dec-28-21 05:57PM
02:50PM
10:00AM
Dec-27-21 03:16PM
11:00AM
Dec-26-21 08:32AM
Dec-24-21 06:13PM
01:56PM
10:40AM
Dec-23-21 08:38PM
09:30AM
Dec-22-21 06:22PM
05:59PM
04:50PM
02:32PM
11:00AM
10:00AM
Dec-21-21 05:54PM
04:08PM
11:00AM
09:30AM
07:38AM
Dec-20-21 05:47PM
03:49PM
11:00AM
11:00AM
10:00AM
Dec-19-21 09:00PM
08:32AM
Dec-17-21 06:13PM
05:00PM
01:40PM
12:32PM
09:45AM
Dec-16-21 03:50PM
03:00PM
11:00AM
11:00AM
12:49AM
Dec-15-21 05:59PM
04:00PM
01:36PM
12:15PM
09:10AM
Dec-14-21 09:00PM
01:53PM
12:45PM
10:12AM
09:34AM
Dec-13-21 10:00PM
06:57PM
05:15PM
04:30PM
03:38PM
01:20PM
10:15AM
Dec-12-21 09:00PM
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DGP Co., Ltd.10% OwnerFeb 29 '24Sale1.323,400,0004,488,0000Mar 04 06:36 PM